Blood Screening Market Trends

Growth Drivers

• Customized blood matching: It is considered to be essential because the existence of an incompatible blood type tends to trigger a critical immune response, which can potentially lead to death or hemolytic anemia, thereby driving the blood screening industry. In this regard, the June 2023 American Cancer Society article denoted that for blood group A, the A antigen, anti-B, along with Blood group O and A, effectively matches. Simultaneously, for blood group B, the B antigen, anti-A antibodies, and blood groups O and B are suitable, thereby suitable for the market’s continuous upliftment.
• Blockchain for tracing blood: The presence of regulatory uncertainty, ecosystem application, and combating scalability has augmented the blockchain integration in the healthcare industry, which is positively impacting the blood screening sector globally. According to a report published by the Journal of Network and Computer Applications in June 2023, the smartpool technique in blockchain minimizes 51% of attacks, which gradually augments security. Therefore, this is suitable for effectively managing blood screening-based devices, which, in turn, deliberately enhances the market’s exposure internationally.
• Increased telepathology integration: The provision of rapid, remote, and accurate pathology consultations and diagnoses, particularly in underserved locations, is uplifting telepathology adoption, which is positively impacting the blood screening market. Regarding this, a cross-sectional study was published by NLM in November 2023, wherein 388 participants were included. Overall, 80.3% were aware of telepathology, 88.1% were inclined towards its approval, and 89.9% considered an optimistic approach to its potentiality, thereby suitable for its integration during blood screening.

Adverse Transfusion Events Impact on the Market

Estimated Risk Per Unit of Red Blood Cells (RBCs)

Sources: NLM, June 2023

HIV Incidences Driving the Market Demand

2023 International HIV Epidemic

Source: HIV Government, February 2025

Challenges

• Cost-effective gaps among patients: Out-of-pocket expenses in developing regions prevent the majority from accessing suitable blood screening, which has caused a hindrance in the market’s growth. However, manufacturers have implemented different strategies to combat this barrier through private and public collaborations, cross-subsidization, and the presence of ultra-low-cost tests. Besides, sustainability is still a challenging aspect due to which testing rates have gradually reduced overnight. On the contrary, a few countries are experimenting with advanced financing, which denotes a growth opportunity for the market globally.
• Disruptions in the supply chain: Manufacturers in the market experience increased vulnerabilities in the supply chain that threaten the international availability of the market. The overall industry depends on specialized suppliers, with the majority of NAT enzymes sourced from three Germany-based firms. This, however, has developed systemic risks due to which the NAT test production diminished. Besides, the COVID-19 impact revealed other weaknesses, such as delays in shipping and increased lead times for components, thus creating a negative impact on the market.